Tilia Fiduciary Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
APM
Tilia Fiduciary Partners's ARKG Position: Q2 2022 in Review
Tilia Fiduciary Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 101 shares — an estimated $5K sold.
Tilia Fiduciary Partners first reported a position in ARKG in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 334 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.
- Tilia Fiduciary Partners reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
- Tilia Fiduciary Partners sold 101 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $5K.
- Tilia Fiduciary Partners first reported a position in ARK Genomic Revolution ETF in Q1 2022 and held it in 1 quarter.
- Tilia Fiduciary Partners's ARK Genomic Revolution ETF position peaked at $5K in Q1 2022.
- 334 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.
Based on Tilia Fiduciary Partners's 13F filing for Q2 2022, filed 1 Aug 2022.